Prevalence of Heparin-induced Thrombocytopenia in patients with cardiovascular disease admitted to Shahid Beheshti Hospital in Kashan in 1999

History and Objectives: Considering the extensive use of heparin as an anticoagulant and because of the controversial reports on the prevalence of heparin-induced thrombocytopenia (HIT) in different studies, this study was conducted in the cardiology ward of Shaheed Beheshti hospital in Kashan to determine the prevalence of HIT. Materials and Methods: The descriptive strategy of this study was carried out on 400 patients. Patients with a diagnosis of cardiovascular disorder were selected to consume heparin at an appropriate treatment dose and initially did not have thrombocytopenia and patients with such a condition were excluded from the study. Thereafter, cell count was conducted very two day. Results: The study was performed on 400 patients with angina pectoris (65) and myocardial infarction (35) (67 out of them were male and the remainder (33) was female). None of them showed signs of thrombocytopenia. Conclusion: It appears that in contrast to results of other studies with an incidence of 30 for thrombocytopenia, this complication is a rare one and it is not essential to conduct expensive and troublesome methods of platelet counts for related patients

Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human TÂ cells

Although remarkable results have been attained by adoptively transferring T cells expressing fully murine and/or humanized anti-CD19 chimeric antigen receptors (CARs) to treat B cell malignancies, evidence of human anti-mouse immune responses against CARs provides a rationale for the development of less immunogenic CARs. By developing a fully human CAR (huCAR), these human anti-mouse immune responses are likely eliminated. This, perhaps, not only increases the persistence of anti-CD19 CAR T cells�thereby reducing the risk of tumor relapse�but also facilitates administration of multiple, temporally separated doses of CAR T cells to the same recipient. To these ends, we have designed and constructed a second-generation fully human anti-CD19 CAR (or huCAR19) containing a fully human single-chain variable fragment (ScFv) fused with a CD8a hinge, a 4-1BB transmembrane domain and intracellular T cell signaling domains of 4-1BB and CD3z. T cells expressing this CAR specifically recognized and lysed CD19 + target cells produced cytokines and proliferated in vitro. Moreover, cell volume data revealed that our huCAR construct cannot induce antigen-independent tonic signaling in the absence of cognate antigen. Considering our results, our anti-CD19 huCAR may overcome issues of transgene immunogenicity that plague trials utilizing CARs containing mouse-derived ScFvs. These results suggest that this huCAR19 be safely and effectively applied for adaptive T cell immunotherapy in clinical practice. © 2018 Wiley Periodicals, Inc